Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen.
One of the current goals in vaccine development is the noninvasive administration of protective antigens via mucosal surfaces. In this context, the gut-associated lymphoid tissues have already been extensively explored. Vaccination via the nasal route has only recently been the focus of intensive in...
Uloženo v:
| Vydáno v: | Infect Immun |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Microbiology (ASM)
1997
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC176094/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9009311/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/iai.65.2.544-550.1997 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|